








| | | | |
|--|---|---|--|
| | | DAY 1: Monday, June 6, 2016 | |
| | | EDUCATIONAL SESSIONS | |
| 9:00-11:00 Room ES1.5077 |  | Dr. Robert Hambalek INTRODUCTION TO HYPHENATED NMR TECHNIQUES: BIOCHEMICAL / BIOMEDICAL APPLICATIONS | |
| 9:00- 11:00 Room E01.5135 |  | Dr. Min Fu ADVANCED MICROSCOPY FOR DRUG DISCOVERY | |
| 11:00-12:00 Room EM3.2225 |  | Dr. Barry Bedell MRI AND PET OF RODENT BRAINS | |
| 13:00-15:00 Room ES1.5077 |  | Dr. Kurt Dejgaard PRACTICAL PROTEOMICS | |

| | | |
|---|---|--|
| <p>15:00-17:00 Room EM3.2225</p> |  | <p>Dr. Jeff Xia METABOLOMICS – FROM BASIC CONCEPTS TO PRACTICAL DATA ANALYSIS</p> |
|---|---|--|


| | | |
|---|---|--|
| | | <p>DAY 5: Friday, June 10, 2016</p> |
| | | <p>EDUCATIONAL SESSIONS</p> |
| | | <p>Theoretical Part (see Symposium IV)</p> |
| <p>10:00-11:00 Room ES1.5077</p> |  | <p>Dr. Pierre Chaurand MATRIX AND METAL ASSISTED LASER DESORPTION IONIZATION FOR HIGH SPACIAL RESOLUTION IMAGING MASS SPECTROMETRY OF LIPIDS FROM THIN TISSUES SECTIONS</p> |
| <p>13:00-15:00 Room ES1.5077</p> |  | <p>Dr. Ante Padjen SPECIAL TRAINING IN PHARMACOGENOMICS AND PHARMACOKINETICS</p> |

SPEAKER BIOGRAPHIES



Dr. Robert Hambalek was born in Montreal, Canada. He received a B.Sc. degree (with honors) in chemistry from Concordia University, Montreal, Canada, in 1986, and a Ph.D. degree in chemistry from McGill University, Montreal, Canada, in 1991. He then joined Phoenix International Life Sciences in 1991, which later became MDS Pharma Services. There he built up and expanded the chemistry division as its director until 2005. He then joined SynFine Research as the director of the chemistry department in 2006 and 2007. Since 2008, he has been the President and CEO of AptoChem, a company he co-founded with other MDS Pharma chemists. AptoChem specializes in the synthesis of isotopically labeled pharmaceutical research products.

Dr. Hambalek is a member of the American Chemical Society.



Dr. Min Fu obtained her PhD degree from Tsinghua University and the University of British Columbia. She received her post-doctoral fellowship training at the University of British Columbia. Dr. Fu became the Imaging Core Facility manager of the Life Sciences Institute - University of British Columbia (LSI-UBC Imaging) in 2009. Dr. Fu has joined the Research Institute of the McGill University Health Centre (RI-MUHC) since 2012 as the manager of the Molecular Imaging Core Facility. Dr. Fu's expertise is primarily on cell biology and molecular & cellular imaging.



Dr. Jeff Xia Dr. Jeff Xia obtained his Bachelor of Medicine (5-yr program) from Peking University Health Science Center, China, in 2001. He then moved to Canada in 2004 and obtained his MSc degree (research field: Immunology & Genetics) in 2006, followed by his PhD (research field: Bioinformatics & Metabolomics) in 2011, at the University of Alberta, Canada. From 2012-2014, he did his postdoctoral training (research field: Next-generation Sequencing & Systems Biology) at the University of British Columbia, Canada. Since 2015, he has been an Assistant Professor at McGill University. His research (xialabresearch.com) focuses on understanding the interactions between host, gut microbiota and intestinal parasites using metabolomics and systems biology approaches. He is the author of 43 peer-reviewed papers.



Dr. Kurt Dejgaard received his PhD from the European Molecular Biology Laboratories (EMBL) in Heidelberg, Germany and has throughout his career worked with and developed basic and specialized techniques in protein chemistry, protein interactomics and phosphoprotein analyses. He has 10 years of experience in mass spectrometry, operating ion traps, QTOFs and Orbitraps. Dr. Dejgaard has been involved in organizing and teaching practical training courses at McGill and was teacher/instructor on 8 international FEBS practical courses in Europe through the 1990s, in the fields of cell biology and protein chemistry. Dr. Dejgaard was manager of the Proteomics Core Facility at Dept of Biochemistry, McGill, from 2005 to 2011, manager of the Clinical Proteomics

platform at the RI-MUHC from 2011 to 2014 and has since 2014 been director of the Mass Spectrometry Facility at Biochemistry, McGill.

Dr. Pierre Chaurand (Ph.D. 1994, Université Paris Sud, Orsay, France) is Associate Professor of Chemistry at the Université de Montréal (2009 - present). His expertise's are in fundamental and analytical mass spectrometry. With over 18 years of experience in the field, he is one of the pioneers of



the imaging mass spectrometry (IMS) technology. His research interests are focused on the development of new strategies and methods to improve the specificity and sensitivity of IMS with applications in fundamental and clinical biology. Dr. Chaurand has over 80 peer reviewed publications and book chapters in the field of MS, with over 40 in the specific field of IMS including several with cancer and neurologic relevance. His laboratory is equipped with state-of-the-art instrumentation for the processing and preparation of tissue sections and IMS data acquisition and analysis. His research staff is currently comprised of 1 post-doctoral fellow as well as 4 PhD and 1 MSc graduate students.



Dr. Barry Bedell is an Associate Professor in the McGill Department of Neurology & Neurosurgery. Dr. Bedell has a B.S. in Chemistry and a Ph.D. in Medical Physics. He completed a post-doctoral fellowship in MRI physics at the University of Texas Medical Center at Houston. He then received his M.D. from McGill and then completed residency training in Anatomical Pathology at McGill. He joined the McGill Faculty of Medicine in 2006 and started the Small Animal Imaging Lab (SAIL) at the Montreal Neurological Institute. In 2015, Dr. Bedell moved his research activities to the Research Institute of the McGill University Health Centre at the new Glen campus. His research currently focuses on improving our understanding of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, through the seamless integration of multi-modality *in vivo* imaging and quantitative neuropathology.